Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
21 CFR 606.100(c). Record review prior to release All records pertinent to a lot or unit were not reviewed before the release or distribution of a lot or unit of final product.
Voluntary Action Indicated (VAI)
Mar 17, 2010
Biologics · Blood and Blood Products
3 cited references
21 CFR 606.100(c). Record review prior to release All records pertinent to a lot or unit were not reviewed before the release or distribution of a lot or unit of final product.
21 CFR 606.100(c). Thorough investigations Failure to perform a thorough investigation and make a record of the conclusions and follow-up of an unexplained discrepancy.
21 CFR 606.100(b). Establish, maintain and follow manufacturing SOPs Written standard operating procedures including all steps to be followed in the processing and distribution of blood and blood components for homologous transfusion are not always followed.
An FEI (FDA Establishment Identifier) names one physical site. Inspections, outcomes and citations come from FDA's Data Dashboard; FDA posts citations only for some inspections. Recalls come from FDA's enforcement reports (iRES), one row per recall even when it covers many lots. A contract site can make products for many companies, so the company shown is the one FDA lists as the site's firm. Form 483 observations are read by Arca from the 483s FDA posts in its FOIA reading room, most of them scans: the first sentence of each observation, with redactions as FDA made them. FDA posts 483s for a minority of inspections.FDA Data Dashboard, warning letters and enforcement reports